IMPROVED THERAPY FOR HEMOPHILIA AND HEREDITARY BLEEDING DISORDERS

The summary for the IMPROVED THERAPY FOR HEMOPHILIA AND HEREDITARY BLEEDING DISORDERS Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	IMPROVED THERAPY FOR HEMOPHILIA AND HEREDITARY BLEEDING DISORDERS
	CFDA Number:	93.839
	CFDA Description:	Blood Diseases and Resources Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-HL-04-032
	Document Type:	Modification to Previous Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Jun 21, 2004
	Creation Date:	Jan 04, 2008
	Original Closing Date for Applications:	Jan 14, 2020
	Current Closing Date for Applications:	Information not provided
	Archive Date:	Jan 15, 2005
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	$250,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: Special district governments City or township governments Private institutions of higher education For profit organizations other than small businesses State governments Small businesses Public and State controlled institutions of higher education Independent school districts Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility: Information not provided
Grant Description: The National Heart, Lung, and Blood Institute (NHLBI) and the National Hemophilia Foundation (NHF) invite applications for studies that will lead to improved treatment of hemophilia, von Willebrand disease, and other hereditary bleeding disorders with the ultimate goal of finding a cure for bleeding disorders. The objectives of this program are to stimulate research to improve therapy, and enhance understanding of immune response and safety issues related to novel therapeutics, gene transfer or cell based therapies for bleeding disorders.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-04-032.html http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-04-032.html
Grant Announcement Contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster
Similar Government Grants: • Safe and Effective Instruments and Devices for Use in the Neonatal Intensive Care Units (STTR) [R41]; • Safe and Effective Instruments and Devices for Use in the Neonatal Intensive Care Units (SBIR) [R43]...; • Clinical Trials Planning Studies for Rare Thrombotic and Hemostatic Disorders (U34); • Clinical Trials Development Resource for Hematologic Disorders (U24); • Early-Phase Clinical Trials for Blood Cell Therapies (R01); • Clinical Hematology Research Career Development Program (K12); • MOLECULAR MECHANISMS UNDERLYING DIAMOND-BLACKFAN ANEMIA AND OTHER CONGENITAL BONE MARROW FAILURE SYN...; • SPECIALIZED CENTERS OF CLINICALLY ORIENTED RESEARCH (SCCOR) IN TRANSFUSION BIOLOGY AND MEDICINE; • MYELODYSPLASTIC SYNDROME (MDS): SEEKING CURE THROUGH DISCOVERY ON PATHOGENESIS AND DISEASE PROGRESSI...; • Sickle Cell Disease Clinical Research Network